April 30, 2014 | The United States Food and Drug Administration (FDA) has approved the start of multi-center Phase II clinical trials in the United States to treat amyotrophic lateral sclerosis (ALS). The treatment will use adult stem cell technology, first introduced by the Hadassah Medical Center’s Professor Dimitrios Karussis, Senior Neurologist and head of Hadassah’s Multiple Sclerosis Center.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024

TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024

Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024

BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments